Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS

Who May Qualify: - ≥ 40 weeks corrected gestational age to \< 18 years; AND - Admission to the PICU or CICU; AND - Onset of ≥ 2 new organ dysfunctions within the last 3 calendar days (compared to pre-sepsis baseline) as measured by the modified Proulx criteria; AND - Documented or suspected infection as the MODS inciting event. Who Should NOT Join This Trial: - Weight \<3kg; OR - Limitation of care order at the time of screening; OR - Patients at high likelihood of progression to brain death in opinion of the clinical team; OR - Moribund condition in which the patient is unlikely to survive the next 48 hours in opinion of the clinical team; OR - Current or prior diagnosis of hemophagocytic lymphohistiocytosis or macrophage activation syndrome; OR - Peripheral white blood cell count \< 1,000 cells/mm3 as the result of myeloablative therapy OR receipt of myeloablative therapy within the previous 14 days; OR - Known allergy to anakinra, or E. coli-derived products; OR - Known pregnancy; OR - Lactating females; OR - Receipt of anakinra within the previous 28 days; OR - Resolution of MODS by MODS Day 2; OR - Previous enrollment in the TRIPS study. Always talk to your doctor about whether this trial is right for you.